Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 4/20 | 0.41 |
| ▸ | PNMT | P11086 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5108087 | 0.82 | CYP3A4 (0.50) | CYP3A4TSHRALOX15SMN1; SMN2ALDH1A1 | |
| SCHEMBL535139 | 0.81 | CYP3A4 (0.54) | CYP3A4TSHRALOX15SMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL5095072 | 0.80 | TSHR (0.48) | CYP3A4TSHRALOX15SMN1; SMN2ALDH1A1 | |
| SCHEMBL701343 | 0.80 | CYP2A6 (0.48) | CYP3A4TSHRALOX15SMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL25368153 | 0.79 | CYP3A4 (0.52) | CYP3A4TSHRALOX15SMN1; SMN2ALDH1A1 | |
| SCHEMBL703030 | 0.79 | CYP3A4 (0.52) | CYP3A4TSHRALOX15SMN1; SMN2ALDH1A1 | |
| SCHEMBL775187 | 0.79 | CYP3A4 (0.52) | CYP3A4TSHRALOX15SMN1; SMN2ALDH1A1 | |
| SCHEMBL3786384 | 0.79 | CYP3A4 (0.52) | CYP3A4TSHRALOX15SMN1; SMN2ALDH1A1 | |
| SCHEMBL6055610 | 0.79 | CYP3A4 (0.52) | CYP3A4TSHRALOX15SMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL27971896 | 0.79 | CYP3A4 (0.52) | CYP3A4TSHRALOX15SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101203244-A | Compositions of rennin inhibitor and insulin secernent or insulin sensitizer | NOVARTIS AG (CH) | 2008-06-18 | — | — | CN | claimed |
| CN-101163504-A | Combination therapy | XENON PHARMACEUTICALS INC (CA) | 2008-04-16 | — | — | CN | claimed |
| CN-115925642-B | Synthesis method of 1, 4-benzodiazepine Zhuo Zahuan derivative | 枣庄学院 | 2025-02-07 | — | — | CN | disclosed |
| US-20240400583-A1 | TRICYCLIC SULFAMIDES AND SULTAMS | MERCK SHARP & DOHME LLC (US) | 2024-12-05 | — | — | US | disclosed |
| CN-115785002-B | Synthesis method of quinazoline heterocyclic derivative | 枣庄学院 | 2024-10-11 | — | — | CN | disclosed |
| US-20240294548-A1 | TRICYCLIC SULTAMS AND SULFAMIDES AS ANTITUMOR AGENTS | PELOTON THERAPEUTICS INC. | 2024-09-05 | — | — | US | disclosed |
| CN-118530186-A | Synthesis method of quinazoline derivative | 多氟多新材料股份有限公司 | 2024-08-23 | — | — | CN | disclosed |
| EP-4416136-A1 | TRICYCLIC SULFAMIDES AND SULTAMS | Merck Sharp & Dohme LLC (US) | 2024-08-21 | — | — | EP | disclosed |
| EP-4387610-A1 | TRICYCLIC SULTAMS AND SULFAMIDES AS ANTITUMOR AGENTS | Peloton Therapeutics, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20240018125-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | ERMIUM THERAPEUTICS (FR) | 2024-01-18 | — | — | US | disclosed |
| WO-2023202583-A1 | FXR REGULATOR AND USE THEREOF | 北京大学 | 2023-10-26 | — | — | WO | disclosed |
| US-7119088-B2 | Triazole compounds useful in therapy | PFIZER INC. (US) | 2006-10-10 | — | — | US | disclosed |
| US-20060194794-A1 | Triazole compounds useful in therapy | PFIZER INC | 2006-08-31 | — | — | US | disclosed |
| EP-1597260-A1 | TRIAZOLE COMPOUNDS USEFUL IN THERAPY | Pfizer Limited (GB) | 2005-11-23 | — | — | EP | disclosed |
| US-20050049255-A1 | Therapeutic combinations | PFIZER INC | 2005-03-03 | — | — | US | disclosed |
| WO-2004108138-A1 | THERAPEUTIC COMBINATIONS COMPRISING PDE INHIBITORS AND VASOPRESSIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DYSMENORRHOEA | PFIZER LIMITED (GB) | 2004-12-16 | — | — | WO | disclosed |
| WO-2004108138-A1 | THERAPEUTIC COMBINATIONS COMPRISING PDE INHIBITORS AND VASOPRESSIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DYSMENORRHOEA | PFIZER LIMITED (GB) | 2004-12-16 | — | — | WO | disclosed |
| US-20040186091-A1 | A bi-heterocycle-4H-2,3,5,10b-tetraaza-benzo[e]azulene derivatives; for therapy of dysmenorrhoea, anxiety disorder, asthma, atherosclerosis, cardiac failure, cardiovascular disease, cataract, central nervous system disease, motion sickness, Raynaud's disease, rheumatoid arthritis; chemical synthesis | PFIZER INC | 2004-09-23 | — | — | US | disclosed |
| WO-2004074291-A1 | TRIAZOLE COMPOUNDS USEFUL IN THERAPY | PFIZER LIMITED (GB) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004074291-A1 | TRIAZOLE COMPOUNDS USEFUL IN THERAPY | PFIZER LIMITED (GB) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194794-A1 | Triazole compounds useful in therapy | CYP3A43, CYP3A5, CYP3A7 | CYP3A4 5/4885TSHR 1046/4885ALOX15 945/4885 |
| US-20240018125-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | CXCR4, CXCR1, CXCL12 | CYP3A4 4526/4885TSHR 1575/4885ALOX15 3070/4885 |
| US-20050049255-A1 | Therapeutic combinations | AVPR2, AVPR1B, AVPR1A | CYP3A4 4560/4885TSHR 196/4885ALOX15 4216/4885 |
| US-20040186091-A1 | A bi-heterocycle-4H-2,3,5,10b-tetraaza-benzo[e]azulene derivatives; for therapy of dysmenorrhoea, anxiety disorder, asthma, atherosclerosis, cardiac failure, cardiovascular disease, cataract, central nervous system disease, motion sickness, Raynaud's disease, rheumatoid arthritis; chemical synthesis | CNR1, NR1H2, OXER1 | CYP3A4 496/4885TSHR 387/4885ALOX15 140/4885 |
| US-20240294548-A1 | TRICYCLIC SULTAMS AND SULFAMIDES AS ANTITUMOR AGENTS | DCAF15, RBM39, DCAF1 | CYP3A4 2914/4885TSHR 4019/4885ALOX15 3582/4885 |
| US-20240400583-A1 | TRICYCLIC SULFAMIDES AND SULTAMS | DCAF15, RBM39, CARM1 | CYP3A4 3289/4885TSHR 3992/4885ALOX15 3533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.